Allergan has announced it will establish a research and development (R&D) site in Cambridge, Massachusetts.The site will be led by Don Frail, PhD, Senior Vice President of Research and External Scientific Innovation (RESI) and Non-Clinical and Translational Sciences.

Dr. Frail joined Allergan in 2014, relocating from Boston to the Allergan R&D center in Irvine, California, and has led the Research, Clinical Pharmacology, Toxicology and ADME departments, including the External Science & Innovation initiatives to evaluate and implement partnerships and acquisitions across Allergan’s four key therapeutic areas. He will continue to lead the Irvine team as well. Previously, Dr. Frail led the Emerging Innovations Unit at AstraZeneca, the Indications Discovery Units at Pfizer, and the CNS Discovery organization at Pharmacia.

Source: Allergan